KRAS G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma
Abstract
KRAS G12C is the most common KRAS mutation in primary lung adenocarcinoma. Phase I clinical trials have demonstrated encouraging clinical activity of KRASG12C inhibitors in the metastatic setting. We investigated disease-free survival (DFS) and tumor genomic features in patients with surgically resected KRASG12C-mutant lung adenocarcinoma.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 16, 2021
- Source ID
- 10.1158/1078-0432.ccr-20-4772
Entities
People
- Alexander Drilon
- Bob T. Li
- Brooke Mastrogiacomo
- Charles Rudin
- Daniela Molena
- David Lyden
- David R Jones
- Francisco Sanchez-vega
- Gaetano Rocco
- Gregory D Jones
- Gregory J. Riely
- Haiying Zhang
- James G. Connolly
- James M. Isbell
- Kathryn C Arbour
- Kay See Tan
- Matthew J. Bott
- Neal Rosen
- Piro Lito
- Prasad S Adusumilli
- Raul Caso
- Rona Yaeger
- Sandra Misale
- Smita Sihag
- Valerie W. Rusch
- Yonina R Murciano-Goroff
- Yuan Liu
Organizations
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute
- United States Department of Defense
- Weill Cornell Medical Center